Castle Biosciences raises 2025 revenue guidance to $310M-$320M following strong Q2 execution and test volume growth
Source: SeekingAlpha
2025-08-04 22:22:36 ET
More on Castle Biosciences
- Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript
- Castle Biosciences Q2 2025 Earnings Preview
- Castle Biosciences, Revolution Medicines get FDA breakthrough statuses
- Seeking Alpha’s Quant Rating on Castle Biosciences
- Historical earnings data for Castle Biosciences
Read the full article on Seeking Alpha
For further details see:
Castle Biosciences raises 2025 revenue guidance to $310M–$320M following strong Q2 execution and test volume growth
Castle Biosciences Inc.
NASDAQ: CSTL
CSTL Trading
1.08% G/L:
$25.32 Last:
82,523 Volume:
$25.40 Open:
CSTL Latest News
March 13, 2026 11:02:12 am
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
March 09, 2026 07:00:00 am
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 04, 2026 04:30:00 pm
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB
March 03, 2026 04:30:00 pm
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
CSTL Stock Data
$948,047,644
27,291,396
0.3%
60
N/A
Medical Diagnostics & Screening
Healthcare
US
Friendswood
